9Lun·

Healthcare sector thus also covered and most convinced by J&J🙈🐵

10.09
Johnson&Johnson logo
Compró 7 a 152,56 €
1067,94 €
27
6 Comentarios

Imagen de perfil
For what reason J&J?
2
Imagen de perfil
@Tojasoku I would be interested in that too. I would also be interested to know who was in the comparison group and why they decided against others🤔
1
Imagen de perfil
J&J had a strong correction has now recovered already 2% divi + strong growth in my eyes and in my opinion they have no more hurdles ahead of them in the near future and will grow solidly. Novo nordisk & CVS health were still in the selection...
Imagen de perfil
@Jico Have you looked further into the products? It's always interesting to see what's in the pipeline, especially with pharmaceuticals.
Imagen de perfil
Not every sector has to be covered. Pharma is difficult. You either have to be able to assess the pipeline quite well and still move in highly speculative spheres or you have enormously sporty valued companies in front of your nose or, as in the case of Johnson & Johnson, a blue chip portfolio brake with only moderate growth and the constant danger of slipping into some pharmaceutical scandal.
1
Imagen de perfil
J&j falls. Abott and Amgen are more stable
Únase a la conversación